REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

Continued progress on 5x25 strategy to advance five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products...

Related Keywords

United States ,Cyprus ,American ,Dana Cormack ,Chris Brinzey ,Ultragenyx Pharmaceutical Inc ,Technology Platform ,Technology Platform Licensees ,American Academy Of Ophthalmology ,Rocket Pharmaceuticals Inc ,Nasdaq ,Technology Licensee Program ,Development Expenses ,Exchange Commission ,Corporate Communications ,Securities Exchange ,Manufacturing Innovation Center ,Long Term Follow Up ,Chief Executive Officer ,Biologics License Application ,American Academy ,Duchenne Muscular Dystrophy ,Mucopolysaccharidosis Type ,Hunter Syndrome ,Innovation Center ,Licensee Program Highlights ,Rocket Pharmaceuticals ,Ultragenyx Pharmaceutical ,Ornithine Transcarbamylase ,Administrative Expenses ,Platform Licensees ,Securities Act ,Securities Exchange Act ,Financial Condition ,Tax Benefit ,Regenxbio Inc ,